Vivoryon Therapeutics N.V. Announces Upcoming Financial Report

Author: Dylan Bailey Updated: 08-27-2025 01:28 AM

Vivoryon Therapeutics N.V. to Release Half-Year Financial Results

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) is positioned to unveil its half-year financial results for the period ending June 30, 2025. The announcement comes as the company is dedicated to advancing its clinical stage endeavors, particularly regarding innovative treatments for kidney diseases.

Corporate Update Scheduled for September

The report will provide significant insights into the company's operational progress and future directions. Vivoryon plans to share its findings through a live conference call on September 4, 2025. This event offers an exciting opportunity for stakeholders and interested parties to engage with the management and understand the strategic advancements of the company.

Conference Call Details

The public is invited to join the conference call scheduled for 3:00 pm CEST / 9:00 am EDT. Attendees can participate via phone or through a webcast available directly on the company's website. Pre-registration for the phone call is encouraged to ensure smooth access to the call.

About Vivoryon Therapeutics N.V.

Vivoryon Therapeutics is a dynamic biotechnology firm that is at the forefront of developing cutting-edge small molecule medicines aimed at addressing inflammatory and fibrotic disorders, particularly those affecting kidney health. The company remains committed to scientific excellence and innovation in pursuit of better patient outcomes.

One of the flagship projects, varoglutamstat, represents a pioneering treatment option as an orally available QPCT/L inhibitor. This investigational drug is under evaluation specifically for its potential to treat diabetic kidney disease, showcasing Vivoryon's dedication to tackling complex medical challenges.

Public Engagement and Communication

Vivoryon has emphasized the importance of maintaining transparent communication with stakeholders, providing avenues for inquiries and feedback. The investor relations team plays a critical role in disseminating vital information regarding the company's progress. Anyone interested in learning more about Vivoryon's initiatives is encouraged to reach out.

Contact Information

For further details or inquiries, individuals can contact Vivoryon Therapeutics directly via email at IR@vivoryon.com. This communication ensures that investors and stakeholders are well-informed about developments and announcements related to the company's progress.

Frequently Asked Questions

What financial results will Vivoryon Therapeutics report?

Vivoryon Therapeutics will report its half-year financial results for the period ending June 30, 2025.

When is the conference call for the financial results?

The conference call is set for September 4, 2025, at 3:00 pm CEST / 9:00 am EDT.

How can stakeholders participate in the conference call?

Stakeholders can participate via phone or through a live webcast. Pre-registration for the call is encouraged for phone participants.

What is varoglutamstat?

Varoglutamstat is Vivoryon's advanced investigational drug, aimed at treating diabetic kidney disease.

How can investors contact Vivoryon Therapeutics?

Investors can reach Vivoryon Therapeutics by emailing IR@vivoryon.com for any inquiries or additional information.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.